Answers are grounded in this paper and cite their sources.
Background Ewing sarcoma is a rare, aggressive small round cell sarcoma affecting mainly children, adolescents, and young adults. Evidence on treatment delivery, toxicity, and long-term outcomes in adults remains limited. Methods This retrospective single-center cohort study included patients aged ≥ 16 years treated at the National Cancer Institute, Bratislava, Slovakia, from January 2007 through June 2026 for Ewing sarcoma or selected historical round cell sarcoma diagnoses considered compatible with Ewing sarcoma. Response and toxicity were assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and Common Terminology Criteria for Adverse Events version 5.0 (CTCAE 5.0). Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan–Meier methods; the association of metastatic disease at diagnosis with time-to-event outcomes was explored using univariable Cox proportional hazards models. Median follow-up was estimated using reverse Kaplan–Meier analysis. Results Among 41 patients, median age at diagnosis was 33.6 years (range, 16.7–68.5), and 25 (61.0%) had metastatic disease at diagnosis. A characteristic Ewing sarcoma-associated gene fusion was molecularly confirmed in 19 patients (46.3%). The objective response rate (ORR) was 82.9% (34/41) overall and 85.2% (23/27) among patients who had received neither surgery nor radiotherapy before induction chemotherapy. Median follow-up was 63.7 months (95% confidence interval [CI], 47.7–104.5). Median OS and PFS were 70.3 and 26.4 months, respectively. Metastatic disease was associated with shorter PFS (median, 13.2 vs 75.1 months; hazard ratio [HR], 2.50; 95% CI, 1.02–6.12; Cox model P = .045; log-rank P = .036). OS was numerically shorter in metastatic disease (median, 21.8 months vs not reached; HR, 2.15; 95% CI, 0.81–5.74; Cox model P = .126; log-rank P = .117). Grade 4 neutropenia occurred in 30/41 patients (73.2%), febrile neutropenia in 20/41 (48.8%), and dose reductions were recorded in 25/41 (61.0%). No treatment-related deaths were recorded. Conclusions In this retrospective referral cohort, metastatic disease at diagnosis was associated with significantly shorter PFS, whereas the association with OS was imprecisely estimated and not statistically significant. High response rates coexisted with substantial hematologic toxicity and frequent dose reductions. Interpretation is limited by the small sample size, treatment heterogeneity, and incomplete molecular confirmation.
No takes yet. Share an insight, caveat, or question.
Minařík et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: